Indoco Remedies growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+10.8%−8.4%+8.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+42.9%−59.4%−14.6%
+205.3%−109.6%−29.3%
−26.6%−180.4%−31.8%
−226.5%−19.7%−31.8%
+6.7%+13.3%+29.3%
−8.5%−8.3%+8.0%
+102.5%−39.4%−12.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDOCO₹231.00

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹2,132 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+8.9-8.4+10.8—
EBITDA Growth—-14.6-59.4+42.9—
EBIT Growth—-29.3-109.6+205.3—
Net Income Growth—-31.8-180.4-26.6—
EPS Growth—-31.8-19.7-226.5—
Total Assets Growth—+29.3+13.3+6.7—
Total Equity Growth—+8.0-8.3-8.5—
Cash from Operations Growth—-12.4-39.4+102.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.